Person: ATASOY, BESTE MELEK
Loading...
Email Address
Birth Date
Research Projects
Organizational Units
Job Title
Last Name
ATASOY
First Name
BESTE MELEK
Name
11 results
Search Results
Now showing 1 - 10 of 11
Publication Metadata only Efficacy of protracted dose-dense temozolomide in patients with recurrent high-grade glioma(SPRINGER, 2011) ATASOY, BESTE MELEK; Abacioglu, Ufuk; Caglar, Hale B.; Yumuk, Perran F.; Akgun, Zuleyha; Atasoy, Beste M.; Sengoz, MericThe current standard therapy for newly diagnosed glioblastoma is multimodal, comprising surgical resection plus radiotherapy and concurrent temozolomide, then adjuvant temozolomide for 6 months. This has been shown to provide survival benefits; however, the prognosis for these patients remains poor, and most relapse. The objective of this prospective Phase II study was to evaluate the efficacy and tolerability of protracted, dose-dense temozolomide therapy (100 mg/m(2) for 21 consecutive days of a 28-day cycle) in patients with recurrent glioblastoma or grade 3 gliomas who had previously received standard therapy. Of the 25 patients included (median age 50 years), 20 were evaluable for radiologic response. Two patients had partial responses and 10 had stable disease (60% overall clinical benefit); 8 patients (40%) progressed after the first treatment cycle. Five patients were not assessed for radiologic response due to early clinical progression but were included in the progression-free survival (PFS) and overall survival (OS) analyses. The median follow-up time was 7 months (range, 1-14 months). The median PFS was 3 months (95% confidence interval, CI, 1.8-4.2) and the median OS was 7 months (95% CI 5.1-8.9). The 6-month PFS rate (primary endpoint) was 17.3% (95% CI 1.7-32.2) and the 1-year OS rate was 12% (95% CI -1-25). This regimen was well tolerated. The most frequent adverse event was lymphopenia (grade 3-4 in 20 patients); no opportunistic infections were reported. Treatment was discontinued due to toxicity in 2 patients (grade 4 hepatic toxicity and thrombocytopenia). These data suggest that protracted, dose-dense temozolomide had modest activity with manageable toxicity in patients with recurrent high-grade glioma previously treated with temozolomide.Publication Metadata only Outcome in carcinoma of the uterus with papillary serous and clear cell histology: A Turkish Oncology Group Study(AMER SOC CLINICAL ONCOLOGY, 2008) ATASOY, BESTE MELEK; Yumuk, P. F.; Kucucuk, S.; Atasoy, B. M.; Aydin, A.; Cicin, I.; Yildiz, F.; Atkovar, G.; Aslay, I.; Okkan, S.; Topuz, E.Publication Metadata only Rektum kanseri̇ni̇n adjuvan tedavi̇si̇nde radyoterapi̇yle eş zamanli tegafur urasi̇l uft foli̇ni̇k asi̇t fa uygulamasi tolerabi̇li̇te değerlendi̇rmesi̇(2006-04-19) ATASOY, BESTE MELEK; ÖZGEN, ZERRİN; DANE, FAYSAL; YUMUK, PERRAN FULDEN; ATASOY B. M. , ABACIOĞLU U., ÖZGEN Z., DANE F., YUMUK P. F. , MAYADAĞLI A., TURHAL S., ŞENGÖZ K. M.Publication Metadata only Health-Related Quality of Life During Postoperative Chemoradiotherapy with Oral Uracil-Tegafur and Leucovorin in Rectal Cancer Patients(H G E UPDATE MEDICAL PUBLISHING S A, 2013) ATASOY, BESTE MELEK; Ozgen, Zerrin; Ozden, Sevgi; Dane, Faysal; Atasoy, Beste M.; Akgunt, Zuleyha; Yumuk, P. Fulden; Mayadagli, Alpaslan; Turhal, N. Serdar; Abacioglu, UfukBackground/Aims: The objective of this study was to report on the quality of life of locally advanced rectal cancer patients that were treated with uracil-tegafur (UFT)/leucovorin (LV)-based concurrent chemoradiotherapy. Methodology: Twenty-five patients were enrolled into this prospective study. Radiotherapy (50.4Gy) was given with concurrent UFT (300mg/m(2)/day) and LV (30mg/day). Turkish versions of EORTC-QLQC30 and EORTC QLQCR38 were applied at the beginning (HROoL-1) and at the end (HRQoL-2) of chemoradiotherapy. Paired samples t-test was used to compare the difference of means for each scale between HRQoL1 and HRQoL2 and p values <0.05 were considered statistically significant. Results: Study compliance was 80.6%. From baseline to the end of chemoradiotherapy, the mean scores of dyspnea (p=0.006) diarrhea (p=0.005) and micturition (p=0.005) increased significantly. Chemotherapy side effects also increased at the end of therapy (p=0.07). Seventy-six percent (76%) of male patients replied to questions related to sexual problems and functions, whereas no female patients replied. Conclusions: Although, diarrhea and micturition are the major problems, quality of life scores indicate that concurrent oral fluoropyrimidine-based chemoradiotherapy is a feasible treatment.Publication Metadata only Kanser tanisi alan hastalarda poli̇kli̇ni̇k şartlarinda üç farkli test İle nütri̇syonel durum değerlendi̇rmesi̇(2012-04-19) ATASOY, BESTE MELEK; ÖZGEN, ZERRİN; DANE, FAYSAL; YUMUK, PERRAN FULDEN; Atasoy B. M., Aygör H. A., Günaydın D., Özlen T., İbrahimov R., Özgen Z., Dane F., Yumuk P. F.Publication Metadata only Treatment outcomes of breast cancer patients older than 65 years old received local radiotherapy(2014-09-30) ATASOY, BESTE MELEK; ÖZGEN, ZERRİN; YUMUK, PERRAN FULDEN; UĞURLU, MUSTAFA ÜMİT; KAYA, HANDAN; GÜLLÜOĞLU, MAHMUT BAHADIR; Atasoy B. M., Kefeli A., Özgen Z., Rzayev R., Yumuk P. F., Uğurlu M. Ü., Kaya H., Arıbal M. E., Güllüoğlu M. B.Publication Metadata only Prognostic factors in progressive high-grade glial tumors treated with systemic approach: A single center experience(SAGE PUBLICATIONS LTD, 2021) ATASOY, BESTE MELEK; Alan, Ozkan; Telli, Tugba Akin; Tuylu, Tugba Basoglu; Arikan, Rukiye; Demircan, Nazim Can; Ercelep, Ozlem; Kaya, Serap; Babacan, Nalan Akgul; Atasoy, Beste M.; Bozkurt, Suheyla; Bayri, Yasar; Gul, Dilek; Ekinci, Gazanfer; Ziyal, Ibrahim; Dane, Faysal; Yumuk, P. FuldenPurpose Malignant high-grade gliomas are the most common and aggressive type of primary brain tumor, and the prognosis is generally extremely poor. In this retrospective study, we analyzed the outcome of systemic treatment in recurrent high-grade glioma patients and the impact of prognostic factors on survivals. Methods Data from 114 patients with recurrent high-grade glioma who received systemic treatment and followed in our clinic between 2012 and 2018 were retrospectively analyzed. Eastern Cooperative Oncology Group (ECOG) performance status, age, gender, histology, type of surgical resection, side effects after systemic treatment (deep vein thrombosis, hypertension, proteinuria), IDH1 and alpha thalassemia/mental retardation syndrome X-linked (ATRX) mutation status were investigated as prognostic factors for progression-free survival and overall survival. Results At the time of diagnosis, the median age was 48 (17-77) and 68% of the patients were male. Most common pathologic subtype was glioblastoma multiforme (68%). Median follow-up duration was 9.1 months (1-68 months). Median progression-free survival and overall survival were 6.2 months and 8 months, respectively. In multivariate analysis, ECOG PS, deep venous thrombosis and the presence of ATRX and IDH1 mutation were found to be independent prognostic factors for progression-free survival (p < 0.05) and, ECOG PS, the presence of ATRX and IDH1 mutation for overall survival (p < 0.05). Conclusion Our study is real life data and the median progression-free survival and overall survival rates are similar to the literature. We have found ECOG PS, presence of ATRX and IDH1 mutation to be independent prognostic factors for both progression-free survival and overall survival.Publication Metadata only Translation, validity, and reliability of NUTRISCORE: the nutrition risk assessment screening test for Turkish cancer patients(WILEY) ATASOY, BESTE MELEK; Ak, Elif; Demirel, Birsen; Atasoy, Beste M.; Yumuk, Perran FuldenPurpose The aim was to determine the validity and the reliability of the Turkish version of the screening test named NUTRISCORE in cancer patients. Methods The language validity of the Turkish form of the study scale was provided by the translationback-translation method. NUTRISCORE and nutritional risk screening (NRS)-2002, malnutrition screening tool (MST), and European Diagnostic Criteria (EDC) were administered to 240 volunteers in oncology clinics, and receiver operating characteristic curves (ROC) were calculated for the validity and reliability analysis. Cohen's kappa coefficient was used to determine the fit between the screening tests. Results Thirteen experts were consulted for scale content validity, and the content validity index was found to be 0.94. The scale was administered to 67 patients with 4-week intervals for test-retest reliability, and a positive, high-level and statistically significant relationship was found between the two measurements (r = 0.971, P < 0.01). Compared with the reference test NRS-2002, the specificity values of NUTRISCORE, MST, and EDC screening tests were found to be 100%, 83%, and 91%, whereas the sensitivity values of same screening tests were calculated as 85%, 91% and 81%, respectively. According to Cohen's kappa statistics, the kappa agreement between NRS-2002 and NUTRISCORE was 0.88, the kappa agreement between NRS-2002 and MST was 0.34, and it was found to be 0.73 for NRS-2002 and EDC. Conclusion The nutrition screening test named NUTRISCORE showed adequate validity and reliability in Turkish and can detect malnutrition risk of cancer patients treated in oncology clinics as a screening tool.Publication Metadata only Prognostic value of modified Glasgow prognostic score in recurrent high-grade glial tumors treated with systemic treatment(ELSEVIER, 2020) ATASOY, BESTE MELEK; Alan, Ozkan; Telli, Tugba Akin; Basoglu, Tugba; Arikan, Rukiye; Demircan, Nazim Can; Ercelep, Ozlem; Bozkurt, Suheyla; Atasoy, Beste Melek; Dane, Faysal; Yumuk, Perran FuldenObjectives: Malignant high-grade gliomas are the most common and aggressive type of primary brain tumor. We aimed to evaluate the prognostic value of modified Glasgow Prognostic Score (mGPS), which is combination of C-reactive protein (CRP) and albumin, in recurrent high-grade glioma patients treated with systemic treatment. Patients and Methods: Data of 85 patients with recurrent high-grade glioma who received systemic treatment and followed in our clinic between 2012 and 2018 was retrospectively collected and analyzed. Patients were grouped according to mGPS criteria: mGPS-0: CRP 10 mg/L and albumin 3.5 g/dL or CRP 10 mg/L and albumin > 3.5 g/dL; and mGPS-2: CRP > 10 mg/L and albumin < 3.5 mg/L. We investigated the prognostic role of mGPS groups, mutations and survival outcomes. Results: There were 42 (49.4 %), 25 (29.6 %), and 18 (21 %) patients in mGPS-0, mGPS-1, and mGPS-2 groups, respectively. Median follow-up duration was 10 months (1-70 months). Median OS was 8.1 months. According to mGPS-0,-1 and-2; median OS was 13.8 months, 7.3 months and 3.6 months respectively (p = 0.003). mGPS, ATRX and IDH-1 mutation status, and ECOG PS were found to be independent prognostic factors for OS. Conclusion: In our study, mGPS was found to be an independent prognostic factor in patients with recurrent high-grade gliomas. If validated, mGPS can be used as an objective, easily calculated, cheap, and readily available prognostic model in routine practice.Publication Metadata only Nüks yüksek gradli gli̇al tümörlerde bevasi̇zumabin sağkalim üzeri̇ne etki̇si̇(2012-04-19) DANE, FAYSAL; ATASOY, BESTE MELEK; ÖZGEN, ZERRİN; ALSAN ÇETİN, İLKNUR; YUMUK, PERRAN FULDEN; Dane F., Atasoy B. M., Aktaş B., Özgen Z., Alsan Çetin İ., Abacıoğlu U., Yumuk P. F.Amaç: Bu çalışmada, yüksek gradlı glial tümör tanısı alarak standart tedaviler sonrası nüks etmiş hastalarda tedaviye bevasizumab eklenmesinin sağkalıma etkisinin incelenmesi amaçlanmıştır. Gereç-Yöntem: Şubat 2005-Temmuz 2010 tarihleri arasında 17’si glioblastoma olmak üzere yüksek gradlı glial tümör tanısı almış ortanca yaşı 50 (aralık, 25-62 yaş) toplam 21 (12K:9E) hastanın geriye dönük verileri incelendi. Subtotal eksizyon yapılmış iki ve biyopsi ile tanı konmuş bir hastanın dışında tüm hastalarda (n=18) primer tümör total olarak eksize edilmişti. Postop radyoterapi, eş zamanlı temozolamid 75 mg/m2 ile ortanca 60 Gy olarak uygulanmıştı. Adjuvan dönemde temozolamid 150-200 mg/m2/1-5.günler/28 günde bir olmak üzere ortanca 8 kür (aralık 2-19 kür) devam etmişti. Klinik ve radyolojik progresyon izlenen hastalarda bevasizumab (10 mg/kg/1-14. günler 28. günde bir) tek başına (n=19) ya da irinotekan (n=2) ile birlikte uygulandı. Sağkalım sonuçları Kaplan-Meier eğrisi çizdirilerek elde edildi. Bulgular: Tüm hastalarda cerrahiden itibaren ortanca takip 25 ay (aralık 12-68 ay) idi. Nüks eden hastalardan dördüne cerrahi, altısına Gamma Knife ile stereotaktik radyocerrahi ve altısına da adjuvan temozolamid sonrası yeniden temozolamid (2-10 kür) uygulandı. Standart adjuvan tedavi (kemoradyoterapi ve adjuvan temozolamid) sonrası nüks durumunda doğrudan bevasizumab başlanan dokuz hasta vardı. Nüksten sonra bevasizumab ortanca 6 kür (aralık, 2-27 kür) uygulandı. Hiçbir hastada bevasizumaba bağlı ölüm izlenmedi. Tüm hastalarda cerrahiden itibaren iki yıllık genel sağkalım %62.5 idi. Bevasizumab sonrası ortanca progresyonsuz sağkalım 5 ay (%95 güven aralığı 2.2- 7.8 ay) ve ortanca genel sağkalım 8 ay (%95 güven aralığı 5.1-10.9 ay) idi. Altı aylık progresyonsuz sağkalım %49.1, 6 ve 12 aylık genel sağkalımlar sırasıyla %73.7 ve %39.3 oldu. Sonuç: Nüks yüksek gradlı glial tümörlerde bevasizumab uygulaması diğer tedavilere göre daha yüksek progresyonsuz sağkalım ve genel sağkalım sonuçlarıyla ümit verici bir tedavi olma özelliği göstermektedir.